Biomaterial Database

Best Practices for Microbial Challenge In-use Studies to Evaluate the Microbial Growth Potential of Parenteral Biological Products; Industry and Regulatory Considerations. 2023

Camellia Zamiri, and Danielle L Leiske, and Patricia F Hughes, and J Paul Kirwan, and Evelyn Der, and Emily Cox, and Rob Warburton, and Monica Goss, and Sarah Weiser, and Janet Perez-Brown, and Ganapathy Gopalrathnam, and Jing Liu, and Shyam B Mehta, and Shebeer Shereefa, and Sebastian Specht, and Sandra J Aedo, and Pierre Goldbach, and Feng Jia, and Barbara Kuehnle, and Scott Page, and Liesbeth Voeten, and Li Yi, and Chen Zhu

Pharmaceutical Development, Genentech (A Member of the Roche group), 1 DNA Way, South San Francisco, CA 94080, USA; zamiri.camellia@gene.com.

Microbial challenge in-use studies are performed to evaluate the potential for microbial proliferation in preservative-free single dose biological products after first puncture and potential accidental contamination during dose preparation (e.g. reconstitution, dilution) and storage. These studies, in addition to physicochemical in-use stability assessments, are used as part of product registration to define in-use hold times in Prescribing Information and in the pharmacy manual in the case of clinical products. There are no formal guidance documents describing regulator expectations on how to conduct microbial challenge in-use studies and interpret microbial data to assign in-use storage hold-times. In lieu of guidance, US Food and Drug Administration (FDA) regulators have authored publications and presentations describing regulator expectations. Insufficient or unavailable microbial challenge data can result in shortened in-use hold times, thus microbial challenge data enables flexibility for health care providers (HCPs) and patients, while ensuring patient safety. A cross-industry/FDA in-use microbial working group was formed through the Innovation & Quality (IQ) Consortium to gain alignment among industry practice and regulator expectations. The working group assessed regulatory guidance, current industry practice via a blinded survey of IQ Consortium member companies, and scientific rationale to align on recommendations for experimental design, execution of microbial challenge in-use studies, and a decision tree for microbial data interpretation to assign in-use hold times. Besides the study execution and data interpretation, additional considerations are discussed including use of platform data for clinical stage products, closed system transfer devices (CSTDs), transport of dose solutions, long infusion times, and the use of USP <797> by HCPs for preparing sterile drugs for administration. The recommendations provided in this manuscript will help streamline biological product development, ensure consistency on assignment of in-use hold times in biological product labels across industry, and provide maximum allowable flexibility to HCPs and patients, while ensuring patient safety.